PKS Advisory Services LLC Makes New Investment in Eli Lilly and Company (NYSE:LLY)

PKS Advisory Services LLC acquired a new stake in Eli Lilly and Company (NYSE:LLY) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 622 shares of the company’s stock, valued at approximately $481,000.

A number of other institutional investors have also modified their holdings of LLY. Prestige Wealth Management Group LLC lifted its position in Eli Lilly and Company by 2.0% during the fourth quarter. Prestige Wealth Management Group LLC now owns 606 shares of the company’s stock valued at $468,000 after buying an additional 12 shares in the last quarter. Signature Estate & Investment Advisors LLC raised its stake in shares of Eli Lilly and Company by 3.3% in the 4th quarter. Signature Estate & Investment Advisors LLC now owns 1,320 shares of the company’s stock valued at $1,019,000 after acquiring an additional 42 shares during the period. Syverson Strege & Co acquired a new position in shares of Eli Lilly and Company during the 4th quarter valued at $320,000. Heritage Wealth Management Inc. CA boosted its position in Eli Lilly and Company by 19.9% during the 4th quarter. Heritage Wealth Management Inc. CA now owns 1,049 shares of the company’s stock worth $810,000 after purchasing an additional 174 shares during the period. Finally, Zions Bancorporation N.A. increased its holdings in Eli Lilly and Company by 26.8% in the 4th quarter. Zions Bancorporation N.A. now owns 11,826 shares of the company’s stock valued at $9,130,000 after purchasing an additional 2,496 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at $4,778,521.60. The trade was a 14.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $852.35 on Wednesday. The company has a market cap of $808.17 billion, a P/E ratio of 72.79, a PEG ratio of 1.40 and a beta of 0.34. The business has a 50 day moving average of $839.56 and a two-hundred day moving average of $837.61. Eli Lilly and Company has a 52 week low of $711.40 and a 52 week high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company declared that its Board of Directors has initiated a share repurchase program on Monday, December 9th that allows the company to repurchase $15.00 billion in shares. This repurchase authorization allows the company to repurchase up to 2% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Bank of America restated a “buy” rating and issued a $997.00 price target on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Wells Fargo & Company lifted their price objective on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Morgan Stanley set a $1,146.00 target price on shares of Eli Lilly and Company in a research note on Thursday, March 6th. Finally, Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a research note on Thursday, January 16th. Three equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $1,009.72.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.